Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. (NUVL) – Form 144 filing discloses a planned resale of 4,253 Class A common shares, valued at roughly $349,086, through Goldman Sachs & Co. LLC on or after 24 Jul 2025.
The shares were originally acquired in two public offerings (3,535 on 02 Aug 2021 and 718 on 03 Nov 2022) and equal just ~0.006% of the 66.4 million shares outstanding, implying negligible impact on float or dilution because Rule 144 covers already-issued stock. No sales have occurred in the past three months, and the seller certifies possession of no material non-public information.
The notice contains no operational or earnings data and does not involve new capital for the company; however, investors may view insider disposition—albeit small—as a sentiment indicator to be weighed against broader fundamentals.
Nuvalent, Inc. (NUVL) Form 144 reports a planned insider sale of 156,670 Class A common shares, equal to roughly 0.24 % of the 66.37 million shares outstanding. The proposed transaction, to be executed through Goldman Sachs & Co. LLC, carries an aggregate market value of $12.86 million, implying a reference price near $82 per share. The approximate sale date listed is 24 July 2025 on Nasdaq.
The shares were originally acquired on 30 April 2021 via a purchase of preferred stock that automatically converted to common immediately prior to Nuvalent’s IPO. The filer reports no other share sales in the past three months and certifies that no undisclosed material adverse information is known.
While the notice signals insider intent to monetize a portion of holdings, the size is modest versus float and does not by itself alter Nuvalent’s operating outlook. Investors may monitor subsequent Form 4 filings for execution details and gauge any short-term supply effects.
Form 4 Overview – Nuvalent, Inc. (NUVL)
On 06/26/2025, Chief Development Officer Darlene Noci reported a series of option exercises and related open-market sales under a pre-arranged Rule 10b5-1 trading plan dated 11/18/2024.
- Option exercise: 4,000 Class A common shares were acquired via option exercise at an exercise price of $27.85 per share.
- Dispositions: The exact 4,000 shares were immediately sold in three blocks: 85 sh at a weighted average $77.38, 3,609 sh at $78.70, and 306 sh at $79.15. Aggregate proceeds approximate $311 k, implying a spread of roughly $50 per share over the exercise price.
- Post-transaction holdings: Noci’s direct ownership declined from 52,034 to 48,034 shares (-7.7%). She retains 138,329 stock options expiring 01/06/2033.
No other equity classes or derivative instruments were reported. All transactions were effected under a 10b5-1 plan, suggesting routine portfolio management rather than discretionary selling.
Nuvalent, Inc. (NUVL) – Form 4 insider transaction summary
Chief Scientific Officer Henry E. Pelish reported a series of option exercises and related open-market sales executed on 06/25/2025 and 06/27/2025 under a Rule 10b5-1 trading plan adopted on 11/01/2024.
- Options exercised (Code “M”): 10,800 Class A shares in four tranches – 3,677 and 347 shares at a $27.85 strike (options granted 01/06/2023) and 4,953 and 1,823 shares at a $29.33 strike (options granted 03/01/2023).
- Shares sold (Code “S”): 10,800 Class A shares at weighted-average prices of $79.87 (range $79.80-$79.92) on 06/25/2025 and $79.92 (range $79.80-$80.00) on 06/27/2025.
- Ownership impact: Pelish’s direct Class A common-stock holding remains unchanged at 63,101 shares after the paired exercise-and-sell transactions, indicating a cashless exercise structure.
- Remaining derivative holdings: 28,328 options at a $27.85 strike (expiring 01/06/2033) and 25,299 options at a $29.33 strike (expiring 03/01/2033) are still outstanding.
No new shares were added to, or removed from, insider ownership; the activity primarily generated liquidity while maintaining the existing equity stake. Investors typically view such neutral, plan-based sales as having limited informational content, though they can add modest selling pressure near the $80 trading level.